Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple blood test and ultrasound could revolutionize heart failure diagnosis in family Doctor's office

NCT ID NCT07711821

Diagnosis Sponsor: Universidade do Porto Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This trial investigates whether adding a simple blood test (NT-proBNP) and a quick heart ultrasound (POCUS) to standard care helps doctors diagnose heart failure more accurately in people aged 50 and older. Participants are randomly assigned to receive standard care alone or with one or both of these tests. The study aims to see if these tools lead to more diagnoses and earlier, more effective treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
NT-proBNP testing and cardiac point-of-care ultrasound (POCUS)
What this could lead to
If successful, this approach could make heart failure diagnosis faster and more accurate in primary care, leading to earlier treatment and better quality of life.
What could go wrong
This is a relatively small trial, and the results may not apply to all primary care settings. The diagnostic tools require training and may not be widely available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 160 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

49 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged ≥50 years * Suspected heart failure (based on signs and/or symptoms) OR * Presence of at least two cardiovascular risk factors, including: 1. Diabetes mellitus 2. Arterial hypertension 3. Estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m² 4. Albuminuria 5. Coronary artery disease or prior myocardial infarction or coronary revascularization 6. Stroke or transient ischemic attack 7. Atrial fibrillation or flutter 8. Left ventricular hypertrophy or Q waves on electrocardiogram 9. Obesity (body mass index ≥30 kg/m²) * Ability to provide written informed consent Exclusion Criteria: * Known heart failure under active hospital-based follow-up * Terminal illness or life expectancy \<1 year * Severe comorbid conditions limiting participation or follow-up * Inability to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Unidade de Saúde Familiar Conde da Lousã

    NOT_YET_RECRUITING

    Amadora, Portugal

  • Unidade de Saúde Familiar Garcia Orta

    RECRUITING

    Porto, Portugal

  • Unidade de Saúde Familiar Rodrigues Miguéis

    NOT_YET_RECRUITING

    Lisbon, Portugal

  • Unidade de Saúde Familiar do Parque

    NOT_YET_RECRUITING

    Lisbon, Portugal

More trials for these conditions

Other studies related to the condition(s) this trial covers.